Skip to content

Perineural Dexmedetomidine and Femoral Nerve Block

Perineural Dexmedetomidine as an Adjuvant to Bupivacaine-induced Ultrasound-guided Femoral Nerve Block.

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01964040
Enrollment
45
Registered
2013-10-17
Start date
2013-08-31
Completion date
2014-01-31
Last updated
2013-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Onset and Duration of Sensory and Motor Block of Femoral Nerve,, Time to First Request of Rescue Analgesics,, Total Morphine Consumption in 24 Hours, Visual Analogue Pain Scores,

Keywords

femoral nerve block, peri-neural dexmedetomidine

Brief summary

The duration of sensory block after single dose of long acting local anesthetics is not sufficient to avoid the postoperative use of opioids. Alpha-2 adrenoceptor agonists such as clonidine have been shown to increase the duration of peripheral nerve block. Dexmedetomidine is a more potent and selective α-2-adrenoceptor compared to clonidine. To the best of our knowledge, the use of Dexmedetomidine as adjuvant to local anesthetic was not previously reported for femoral nerve block.

Interventions

ultrasound quided femoral nerve block with injection of 15 ml bupivacaine 0.5% perineurally with 0.5 ml dexmedetomidine (50 microgram) either perineurally or subcutaneously. After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia

Sponsors

anesthesia department
CollaboratorAMBIG
faculty of medicine
CollaboratorAMBIG
Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* all patients with ASA physical status I or II, scheduled for diagnostic knee arthroscopy

Exclusion criteria

* Patients who are refusing regional block, patients with diabetic peripheral neuropathy, renal or hepatic dysfunction, inflammation or infection at the puncture site, and history of allergic reaction to study medications

Design outcomes

Primary

MeasureTime frameDescription
The primary outcome measure of this study will be the change of sensory block over time.intraoperatively every 5 minutes for the first 30 minutes of the operation, then postoperatively every 2 hours for 24hoursOver a period of 30 min after injection of the study medications, a blinded investigator will assess sensory block with pinprick test using a 3-point scale: 0 ═ complete loss of sensation, 1 ═ partial loss of sensation and 2 ═ normal sensation (10). Pinprick test will be done in comparison to the contralateral area at the sensory distribution of the femoral nerve

Secondary

MeasureTime frameDescription
onset of motor and sensory blockup to 30 minutes after the end of injectionThe onset time of sensory and motor block will be: the time elapsed between the end of injection and the development of complete block (score of 0 at all dermatomes or no movement of the quadriceps muscle.

Other

MeasureTime frameDescription
duration of motor blockinterval between time of injection and complete motor power recoverThe duration of motor block will be defined as: the time interval between the end of injection and the complete recovery of motor power of the quadriceps muscle).
Visual analogue pain scores (resting and dynamic) and Richmond Agitation-Sedation Score (RASS) (2hours post operative and for 24hoursVisual analogue pain scores (resting and dynamic) and Richmond Agitation-Sedation Score (RASS) (12) will be assessed at 2, 4, 6, 8, 12, 16, and 24 hours postoperatively
time of 1st request of rescue analgesiaover the poatoperative 24hoursThe time to the first request of rescue postoperative analgesic will be: the time interval between the onset of successful sensory block and the first request to postoperative analgesia

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026